Oral Melatonin Versus Nebulized Dexmedetomidine on Emergence Agitation in Children Undergoing Adenotonsillectomy
Key facts
- Who runs it
- Tanta University
- Where
- Egypt1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 96 people, planned
- Started
- 1 Jul 2025
- Expected to end
- 1 Jul 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Normal saline
- Oral melatonin syrup
- Nebulized dexmedetomidine
- Record updated
- 16 January 2026
Who can take part
- Age
- 3 years to 7 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Children aged between 3 and 7 years
- Both sexes
- Classified as American Society of Anesthesiologists (ASA) physical status I or II according to the American Society of Anesthesiologists
- Scheduled for elective adenotonsillectomy under general anesthesia
Who cannot take part
- Current or recent treatment with anticonvulsants or sedative medications
- Known allergy or hypersensitivity to dexmedetomidine, melatonin or midazolam
- Central nervous system disorders
- Neurological or psychiatric conditions associated with anxiety or agitation (e.g., cerebral palsy, epilepsy, separation anxiety disorder, attention-deficit/hyperactivity disorder)
- Parental refusal to participate in the study
- Presence of developmental delay
- Intellectual disability (formerly termed mental retardation)
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in Egypt.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to compare the efficacy of using oral Melatonin versus nebulized Dexmedetomidine in limitation of emergence agitation in children undergoing adenotonsillectomy.
The 3 groups in the trial
- Group C (Control Group)Existing treatment, for comparison
Participants will receive placebo nebulizer (3 ml of normal saline) without drug and 0.5 mg/kg of midazolam dissolved in Apple Juice.
Treatment: Normal saline
- Melatonin GroupTreatment being tested
Participants will receive placebo nebulizer (3 ml of normal saline) without drug and 0.2 mg/kg of oral melatonin syrup.
Treatment: Oral melatonin syrup
- Dexmedetomidine GroupTreatment being tested
Participants will receive placebo syrup (Apple Juice) and 2 µ/kg nebulized dexmedetomidine prepared in 0.9% normal saline to a final volume of 3ml.
Treatment: Nebulized dexmedetomidine
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparison Between Oral Melatonin Versus Nebulized Dexmedetomidine on Emergence Agitation in Children Undergoing Adenotonsillectomy: A Prospective, Randomized Controlled Trial
- Criteria questions
- Built from NCT07345715, who can take part
- Record updated
- 16 January 2026